Sign In
Buy JAZZ
$240.06
+9.13 (+3.95%)
At Close: Jun 04, 2026
Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma
09:36am, Thursday, 07'th Apr 2022
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has acquired exclusive global development and commercialization rights to Werewolf Therapeutics Inc's (NASDAQ: HOWL) WTX-613. WTX-613 is a differentiated,
Jazz, Werewolf sign licensing deal worth up to $1.2 billion
08:34am, Thursday, 07'th Apr 2022
Shares of Werewolf Therapeutics Inc. jumped 10.8% in premarket trading on Thursday after the company announced a licensing deal with Jazz Pharmaceuticals Plc worth up to $1.2 billion. Jazz now has exc
Expert Ratings For Jazz Pharmaceuticals
04:03pm, Wednesday, 06'th Apr 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Jazz Pharmaceuticals (NASDAQ:JAZZ) stock. These analysts are typically employed by large Wall Street banks and tasked with understand
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
02:16pm, Wednesday, 06'th Apr 2022 Benzinga
Upgrades
According to Morgan Stanley, the prior rating for Royalty Pharma PLC (NASDAQ:RPRX) was changed from Equal-Weight to Overweight. In the fourth quarter, Royalty Pharma showed an EPS of $0.80, c
10 Biggest Price Target Changes For Wednesday
11:14am, Wednesday, 06'th Apr 2022 Benzinga
Raymond James reduced the price target on Intercontinental Exchange, Inc. (NYSE: ICE) from $161 to $157. Intercontinental Exchange shares rose 0.2% to $130.79 in pre-market trading.
Loop Capital cut
3 Biotech Stocks to Buy in April
10:10am, Sunday, 03'rd Apr 2022 The Motley Fool
They're good picks for very different reasons.
3 Biotech Stocks to Buy in April
06:10am, Sunday, 03'rd Apr 2022
They're good picks for very different reasons.
Why Jazz Pharmaceuticals Stock Rose 13.3% in March
05:32am, Saturday, 02'nd Apr 2022 The Motley Fool
The pharmaceutical company specializes in neuroscience and oncology therapies, including some with cannabis compounds.
Why Jazz Pharmaceuticals Stock Rose 13.3% in March
01:32am, Saturday, 02'nd Apr 2022
The pharmaceutical company specializes in neuroscience and oncology therapies, including some with cannabis compounds.
3 CEOs to Invest In
01:00am, Saturday, 02'nd Apr 2022 The Motley Fool
Looking for a healthcare stock with strong leadership? Our roundtable likes Immunocore, Axsome Therapeutics, and GlaxoSmithKline.
Jazz (JAZZ) Up 2.8% Since Last Earnings Report: Can It Continue?
03:30pm, Thursday, 31'st Mar 2022 Zacks Investment Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz (JAZZ) Up 2.8% Since Last Earnings Report: Can It Continue?
12:47pm, Thursday, 31'st Mar 2022
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Biotech Stock Roundup: AXSM to Acquire JAZZ's Drug, IGMS Up on SNY Deal & More
05:29pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
Acquisition and collaboration news from Axsome (AXSM) and IGM Biosciences, Inc. (IGMS), respectively, are a few key highlights from the biotech sector during the past week.
Why Axsome Therapeutics Crushed the Market Again Today
10:19pm, Tuesday, 29'th Mar 2022 The Motley Fool
Two analysts boost their price targets on the company's stock.
Jazz Pharmaceuticals to Participate in Upcoming April Investor Conferences
04:15pm, Tuesday, 29'th Mar 2022
DUBLIN , March 29, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following upcoming investor conferences: J.P. Morgan 11th Annua
